AZD 4785

Drug Profile

AZD 4785

Alternative Names: AZD-4785; IONIS-KRAS-2.5Rx

Latest Information Update: 20 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Nucleotides
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 14 Jun 2017 Pharmacodynamics and adverse events data in Non-small cell lung cancer released by AstraZeneca
  • 15 May 2017 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (IV) (NCT03101839)
  • 15 May 2017 Phase-I clinical trials in Solid tumours (Late- stage disease, Metastatic disease) in USA (IV) (NCT03101839)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top